Alpha Cancer Technologies Inc. is a private clinical stage company with immuno-oncology platform targeting receptors present on almost all solid and liquid tumors and tumor suppressor cells (MDSCs) but absent on normal cells, with additional theranostic applications in development and immunotherapy platform for treating IBD, multiple sclerosis, myasthenia gravis and Hashimoto disease. Our drug platforms use proprietary recombinant human alpha fetoprotein (AFP) with proven safety in over 300 patients.

Bristol Myers Squibb owns a 14% equity interest in the company.

Alpha Cancer Technologies Inc. Logo



Event details

Date: June 10 - 17, 2021

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


30 in total